Rigvir belongs to the immunomodulator group of medicines. As a viral immunomodulator with antitumour effect, Rigvir is registered for treatment of melanoma, local therapy of cutaneous and subcutaneous metastases, prevention of recurrence and metastases after radical surgery.
Rigvir has been used for the following types of tumours:
It is scientifically and practically proven that the following tumour types are sensitive to Rigvir.
sarcoma of several types:
The direct antitumour effect of Rigvir is associated with oncotropism and oncolysis.
The cytolytic effect of the medicine is selective – applies to malignant cells without affecting normal tissue cells.
It is very essential that Rigvir induces the emergence (expression) of tumour-associated differentiation antigens on the surface of non-lysed malignant cells and suppresses the expression of MAGE antigens which are associated with the progressive growth of melanoma.
Altered in such a way, the surface structures of malignant cells become a target for cytotoxic mechanisms of the immune system.
Rigvir mechanism of anticancer activity in humans:
Degenerative-distrophic changes of tumor cells (oncolysis).
Change of cell composition of tumour stroma and intensive lymphoid cell infiltration in the tumour which corresponds to the morphologic view ofimmune rejection.
Following apoptosis of tumour cells (after several Rigvir courses).